fbpx
01 / 05
Humanity Is Winning the War on AIDS

Blog Post | Health & Medical Care

Humanity Is Winning the War on AIDS

In the mid-1990s, there were some 3.4 million new HIV infections each year. In 2017, there were only 1.8 million

Global Number of AIDS Related Deaths, New HIV Infections, and People Living with HIV decreases

Humanity is winning the war on HIV/AIDS. Deaths from the disease are down. The same goes for new infections. More people then ever have access to cheap and effective antiretroviral therapy. Chances are that, in the foreseeable future, a cure or a vaccine will deliver the once terrifying disease a final coup de grâce.

Acquired immune deficiency syndrome (AIDS) is a range of progressively worsening medical conditions caused by infection with the human immunodeficiency virus (HIV) that, if left untreated, usually culminates in death. In the main, HIV spreads through unprotected sex, contaminated blood transfusions, hypodermic needles, as well as from mother to child during pregnancy, delivery and breastfeeding.

Scientists believe that HIV is an offshoot of the simian immunodeficiency virus (SIV) — a virus that attacks the immune system of monkeys and apes. It is thought that the virus “jumped” from simians to humans in the 1920s when Congolese hunters came into contact with animal blood.

First documented cases of people infected with HIV include Congo in 1959, Norway in 1966 and the United States in 1969. In its early days, the disease spread primarily within the gay community, with infection rates of 5 per cent among homosexual men in New York and San Francisco in 1978.

HIV/AIDS was first covered by the mainstream press in 1981 and named one year later. Over time, it has come to affect everyone, with heterosexual men and women accounting for the vast majority of the 76 million people who were infected with the virus and 35 million people who have died from AIDS over the last 40 years.

Considering that HIV is spread, in large part, via sexual intercourse, its destructive potential became obvious very quickly. Consequently, scientists throughout the world have been working on treatments, vaccines and cures for the better part of the last four decades.

The first drugs slowing the progression of HIV appeared in the mid-1990s. Today, it can be treated with highly active antiretroviral therapy (HAART), which not only slows the progression of the virus, but decreases the risk of HIV transmission from one person to another.

The HIV pandemic peaked in the mid-2000s, when some 1.9 million people died of AIDS each year. In 2017, less than one million died from the sickness. In the mid-1990s, there were some 3.4 million new HIV infections each year. In 2017, there were only 1.8 million new HIV infections. In 2017, 37 million people lived with HIV of whom 59 per cent had access to treatment.

Today, sub-Saharan Africa accounts for nearly two-thirds of all people living with the virus. The prevalence of HIV peaked at 5.8 per cent in 2000 and stands at 4 per cent today. The region accounts for nearly two-thirds of all people living with the virus. Of those living with HIV, 44 percent have access to HAART.

In 2000, HAART cost more than $10,000 per patient per year. “Within a year,” the United Nations found, the price “plummeted to $350 per year when generic manufacturers began to offer treatment. Since then, owing to competition among quality-assured generic manufacturers, the cost of treatment continued to fall.”

In 2016, it stood at $64 per patient per year, with much of the money coming from Western aid programmes such as the US President’s Emergency Plan for AIDS Relief.

What does the future hold? So far, the virus has proven fiendishly difficult to eradicate, so we should exercise caution about new medical breakthroughs. That said, today we know more about the disease than ever before and scientists are, probably, closer than ever to a cure or a vaccine.

Late last year, for example, doctors using a treatment called Nivolumab, a cancer drug that was developed by Medarex and brought to market by Bristol-Myers Squibb, noticed a “drastic and persistent” decrease in HIV-infected white blood cells. An HIV vaccine may also be on the horizon after scientists showed that a new drug developed by scientists at Harvard, Massachusetts Institute of Technology and The National Institutes of Health triggered a protective immune response in humans and stopped two thirds of monkeys from becoming infected.

The critics may argue that four decades is a long time to tackle HIV. That, however, is historically illiterate. Smallpox, polio, mumps, Guinea worm disease and malaria have been the scourge of humanity for millennia. Today they are are all either eradicated or treatable. Forty years from an outbreak of a pandemic to treatment and, hopefully, eradication is but the blink of an eye.

This first appeared in CapX.

Medical Xpress | Vaccination

New Vaccine Triggers Immune Response to Fight Brain Tumor

“In a first-ever human clinical trial of four adult patients, an mRNA cancer vaccine developed at the University of Florida quickly reprogrammed the immune system to attack glioblastoma, the most aggressive and lethal brain tumor…

Reported May 1 in the journal Cell, the discovery represents a potential new way to recruit the immune system to fight notoriously treatment-resistant cancers using an iteration of mRNA technology and lipid nanoparticles, similar to COVID-19 vaccines, but with two key differences: use of a patient’s own tumor cells to create a personalized vaccine, and a newly engineered complex delivery mechanism within the vaccine.”

From Medical Xpress.

World Health Organization | Vaccination

Major Step in Malaria Prevention in Three West African Countries

“In a significant step forward for malaria prevention in Africa, three countries—Benin, Liberia and Sierra Leone—today launched a large-scale rollout of the life-saving malaria vaccine targeting millions of children across the three West African nations. The vaccine rollout, announced on World Malaria Day, seeks to further scale up vaccine deployment in the African region.

Today’s launch brings to eight the number of countries on the continent to offer the malaria vaccine as part of the childhood immunization programmes, extending access to more comprehensive malaria prevention. Several of the more than 30 countries in the African region that have expressed interest in the vaccine are scheduled to roll it out in the next year through support from Gavi, the Vaccine Alliance, as efforts continue to widen its deployment in the region in coordination with other prevention measures such as long-lasting insecticidal nets and seasonal malaria chemoprevention.”

From World Health Organization.

World Health Organization | Vaccination

Immunization Efforts Saved 154 Million Lives over past 50 Years

“A major landmark study to be published by The Lancet reveals that global immunization efforts have saved an estimated 154 million lives – or the equivalent of 6 lives every minute of every year – over the past 50 years. The vast majority of lives saved – 101 million – were those of infants.

The study, led by the World Health Organization, shows that immunization is the single greatest contribution of any health intervention to ensuring babies not only see their first birthdays but continue leading healthy lives into adulthood.

Of the vaccines included in the study, the measles vaccination had the most significant impact on reducing infant mortality, accounting for 60% of the lives saved due to immunization. This vaccine will likely remain the top contributor to preventing deaths in the future.”

From World Health Organization.

The Guardian | Vaccination

“Real Hope” for Cancer Cure as Personal mRNA Vaccine Trialled

“Experts are testing new jabs that are custom-built for each patient and tell their body to hunt down cancer cells to prevent the disease ever coming back.

A phase 2 trial found the vaccines dramatically reduced the risk of the cancer returning in melanoma patients. Now a final, phase 3, trial has been launched and is being led by University College London Hospitals NHS Foundation Trust (UCLH).”

From The Guardian.